logo banner home news contact
nav
about argos
history
management team
board of directors

 

Board of Directors

Argos’ seven directors possess extensive experience in science and medicine, industry, and venture capital, providing strategic direction to the Company.

Hubert Birner, Ph.D., M.B.A. TVM Capital Chairman of the Board
Jeffrey D. Abbey, M.B.A., J.D. Argos Therapeutics Director
David W. Gryska Seattle Genetics Director
Jean Lamarre Lamarre Consultants Director
Philip R. (Phil) Tracy, J.D.
Intersouth Partners
Director
Brian J. Underdown, B.Sc., Ph.D. Lumira Capital Director
Sander van Deventer, M.D., Ph.D. Forbion Capital Director



Hubert Birner, Ph.D. M.B.A.
Chairman
Dr. Birner joined TVM Capital in 2000, and is a General Partner for life sciences in the firm’s Munich office. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and is a member of the Board of Directors of Evotec AG (Hamburg, Germany), BioXell SA (Milan, Italy), Spepharm Holding BV (Amsterdam, Netherlands), Proteon Therapeutics, Inc (Kansas City, Missouri), Transmolecular Inc.(Boston, Massachusetts) and Nitec Pharma SA (Basel, Switzerland). Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. Dr. Birner also represents the interests of TVM Capital with Ardana Bioscience plc (Edinburgh, Scotland).
return to top

Jeffrey D. Abbey, M.B.A., J.D.
Director
Jeffrey Abbey joined Argos Therapeutics in 2002. Before joining Argos, Mr. Abbey was Vice President of Business Development and Finance for Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a partner in Eilenberg and Krause, a boutique corporate law firm, where he acted as business counsel for a number of life sciences and other emerging technology companies. Mr. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. He holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.
return to top

David W. Gryska
Director
Mr. Gryska joined our Board of Directors in January 2012. Since March 2005, he also serves as a board member at Seattle Genetics. From December 2006 to October 2010, Mr. Gryska was Senior Vice President and Chief Financial Officer of Celgene. Previously, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. From 1998 to 2004, Mr. Gryska was Senior Vice President and Chief Financial Officer at Scios, Inc., a biopharmaceutical company, where he led the transaction effort for the successful sale of the company to Johnson & Johnson for $2.5 billion in February 2003. From 1993 to 1998, he served as Vice President and Chief Financial Officer at Cardiac Pathways, a company later acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young (EY). During his eleven years at EY, he focused on technology industries, with an emphasis on biotechnology and healthcare companies. Mr. Gryska also serves on the Board of Directors of Hyperion Therapeutics. He holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University.
return to top

Jean Lamarre
Director
Mr. Lamarre joined our Board of Directors in March 2013. As president of Lamarre Consultants, Mr. Lamarre brings to the Board more than 15 years of experience in strategic planning and corporate financing for life sciences and information technology companies. In addition to Argos Therapeutics, Mr. Lamarre sits on numerous boards, including Klox Technologies, Mispro Biotech Services inc. and CQVB. Previously, Mr. Lamarre was Vice President for Canam-Manac Group, one of the largest structural steel companies in North America. While in this role he supervised operations in Mexico, Venezuela, France and China. For 15 years, Mr. Lamarre worked for the Lavalin Group, one of the world´s largest engineering and construction firms. He went from managing international projects in Africa and Central America to CFO of the firm for seven years. He was also European Vice President, supervising operations in Belgium, France and England. Mr. Lamarre holds a Bachelor of Business Administration from HEC Montréal with a specialization in Applied Economics.
return to top

Philip R. Tracy, J.D.
Director
Philip R. Tracy was formerly the President and Chief Executive Officer of Burroughs Wellcome Co., a major research-based pharmaceutical company with $1.2 billion in sales and 5,000 employees. Mr. Tracy has served on the boards of directors of the Pharmaceutical Research and Manufacturers Association of America and the Nonprescription Drug Manufacturers Association. Mr. Tracy is a venture partner with Intersouth Partners and currently serves on the boards of directors of two Intersouth portfolio companies. He is also Of Counsel with Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. He received his B.A. from University of Nebraska and his J.D. from George Washington University.
return to top

Brian J. Underdown, B.Sc., Ph.D.
Director
Brian Underdown joined Lumira Capital (formerly, MDS Capital Corp) in 1997. His focus has been on new company formation in both Canada and the United States. Prior to joining MDSCC, Dr. Underdown held a number of senior management positions in the biopharmaceutical industry and in universities. Dr. Underdown obtained his Ph.D. in immunology from McGill University and undertook post-doctoral studies at Washington University School of Medicine. During his academic career, he focused on immune-mediated diseases as well as vaccine development. During his tenure at MDSCC, Dr. Underdown has focused on new investment opportunities and building value as a board member in a number of companies including, ID Biomedical, Trillium Therapeutics and Cytochroma Inc. He has been actively involved in policy development and grant administration with a number of government and non-governmental organizations that support research, especially as it applies to commercial development.
return to top

Sander van Deventer, M.D., Ph.D.
Director
Sander van Deventer is Professor of Experimental Medicine at the Academic Medical Center in Amsterdam and general partner of Forbion Capital Partners (formerly, ABN AMRO Capital). Dr. van Deventer has held numerous academic appointments and has been the principle clinical investigator for several clinical trials. He has served on a number of regulatory and pharmaceutical industry scientific advisory boards and has been an advisor to the Food and Drug Administration. Dr. van Deventer received his M.D. and Ph.D. from the University of Amsterdam. 
return to top